Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Thomas Joyce, Lawrence Culp, Paul Ladestein

Premium

Danaher said this week that it has appointed Thomas Joyce as president and CEO and member of the board of directors. He replaces Lawrence Culp, who will transition to a senior advisory role with the company.

Joyce started his career with Danaher in 1989 as marketing project manager in the company's tool group, and he also has been president of a truck box and storage container manufacturer and a water analytics firm. In 2002, he became a group executive at Danaher, and since 2006 he has been an executive VP with the company, where he has been responsible for Danaher's Life Sciences and Diagnostics and Water Quality businesses.

Culp will continue as an advisor until March 1, 2016.


Paul Ladestein has been appointed CEO of MyCartis, a new joint venture between Biocartis and Pronota. Ladestein joined Biocartis in 2013 as Evaluation business unit manager after working for Luminex.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.